Immunosuppression on the Horizon

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Many novel immunosuppressive agents are under active clinical investigation. In addition, creative approaches are being developed for the use of established immunosuppressive agents, with the goal of minimizing immunosuppression as early as possible posttransplantation. The hope is that these approaches will minimize the toxicity of these agents without sacrificing efficacy. Evidence suggests that the nephrotoxicity of calcineurin inhibitors can be reduced using these approaches. The introduction of newer immunosuppressive agents, including the proliferation signal inhibitors, raises the possibility that some of the long-term scourges of cardiac transplantation, including cardiac allograft vasculopathy and malignancy, can be ameliorated. Finally, costimulatory pathway inhibitors and other new immunosuppressive agents offer hope that all these goals can be accomplished with very low long-term maintenance immunosuppression.

Original languageEnglish (US)
Pages (from-to)43-49
Number of pages7
JournalHeart Failure Clinics
Volume3
Issue number1
DOIs
StatePublished - Jan 1 2007

Fingerprint

Immunosuppressive Agents
Immunosuppression
Heart Transplantation
Allografts
Neoplasms

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Eisen, Howard. / Immunosuppression on the Horizon. In: Heart Failure Clinics. 2007 ; Vol. 3, No. 1. pp. 43-49.
@article{b37ad773652940c3ab72f49e75af6bf6,
title = "Immunosuppression on the Horizon",
abstract = "Many novel immunosuppressive agents are under active clinical investigation. In addition, creative approaches are being developed for the use of established immunosuppressive agents, with the goal of minimizing immunosuppression as early as possible posttransplantation. The hope is that these approaches will minimize the toxicity of these agents without sacrificing efficacy. Evidence suggests that the nephrotoxicity of calcineurin inhibitors can be reduced using these approaches. The introduction of newer immunosuppressive agents, including the proliferation signal inhibitors, raises the possibility that some of the long-term scourges of cardiac transplantation, including cardiac allograft vasculopathy and malignancy, can be ameliorated. Finally, costimulatory pathway inhibitors and other new immunosuppressive agents offer hope that all these goals can be accomplished with very low long-term maintenance immunosuppression.",
author = "Howard Eisen",
year = "2007",
month = "1",
day = "1",
doi = "10.1016/j.hfc.2007.03.002",
language = "English (US)",
volume = "3",
pages = "43--49",
journal = "Heart Failure Clinics",
issn = "1551-7136",
publisher = "Elsevier Inc.",
number = "1",

}

Immunosuppression on the Horizon. / Eisen, Howard.

In: Heart Failure Clinics, Vol. 3, No. 1, 01.01.2007, p. 43-49.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Immunosuppression on the Horizon

AU - Eisen, Howard

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Many novel immunosuppressive agents are under active clinical investigation. In addition, creative approaches are being developed for the use of established immunosuppressive agents, with the goal of minimizing immunosuppression as early as possible posttransplantation. The hope is that these approaches will minimize the toxicity of these agents without sacrificing efficacy. Evidence suggests that the nephrotoxicity of calcineurin inhibitors can be reduced using these approaches. The introduction of newer immunosuppressive agents, including the proliferation signal inhibitors, raises the possibility that some of the long-term scourges of cardiac transplantation, including cardiac allograft vasculopathy and malignancy, can be ameliorated. Finally, costimulatory pathway inhibitors and other new immunosuppressive agents offer hope that all these goals can be accomplished with very low long-term maintenance immunosuppression.

AB - Many novel immunosuppressive agents are under active clinical investigation. In addition, creative approaches are being developed for the use of established immunosuppressive agents, with the goal of minimizing immunosuppression as early as possible posttransplantation. The hope is that these approaches will minimize the toxicity of these agents without sacrificing efficacy. Evidence suggests that the nephrotoxicity of calcineurin inhibitors can be reduced using these approaches. The introduction of newer immunosuppressive agents, including the proliferation signal inhibitors, raises the possibility that some of the long-term scourges of cardiac transplantation, including cardiac allograft vasculopathy and malignancy, can be ameliorated. Finally, costimulatory pathway inhibitors and other new immunosuppressive agents offer hope that all these goals can be accomplished with very low long-term maintenance immunosuppression.

UR - http://www.scopus.com/inward/record.url?scp=34249696032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249696032&partnerID=8YFLogxK

U2 - 10.1016/j.hfc.2007.03.002

DO - 10.1016/j.hfc.2007.03.002

M3 - Review article

VL - 3

SP - 43

EP - 49

JO - Heart Failure Clinics

JF - Heart Failure Clinics

SN - 1551-7136

IS - 1

ER -